0852 GMT - AstraZeneca's drug pipeline will be the primary focus of Tuesday's earnings call with management, Barclay's analyst write. This follows a second quarter where beats to consensus expectations came from new or core products, and misses to expectations were driven by older products facing generic competition, they write. This is the type of operational performance Barclay's likes to see from AstraZeneca, the analysts write. The earnings call is due to take place at 11:00 GMT. Shares trade up 2.% at 11,004 pence.(adam.whittaker@wsj.com)
(END) Dow Jones Newswires
July 29, 2025 04:52 ET (08:52 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.